The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
The Netherlands Cancer Institute, Scientific Information Service, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Drug Alcohol Depend. 2021 Oct 1;227:108984. doi: 10.1016/j.drugalcdep.2021.108984. Epub 2021 Aug 28.
To review the scientific literature on the pharmacokinetics, pharmacodynamics and clinical efficacy and safety of (supervised) oral diacetylmorphine for patients with severe heroin dependence.
The PubMed, Embase, Web of Science and PsycINFO databases were searched. Eleven published studies were identified and selected based on defined eligibility and exclusion criteria.
Four pharmacokinetic studies reported negligible plasma concentrations of diacetylmorphine and its active metabolite 6-monacetylmorphine. Among six pharmacodynamic studies, three trials showed that oral diacetylmorphine reduced opioid withdrawal symptoms, one open-label pilot study reported that two patients experienced a modest 'rush' after oral diacetylmorphine and two studies found that patients could not distinguish between oral diacetylmorphine, methadone, or morphine. Regarding the clinical studies, a Swiss prospective cohort study in patients with heroin dependence showed high retention rates of oral diacetylmorphine treatment with few serious adverse events, whereas in the Canadian SALOME trial, oral diacetylmorphine treatment was prematurely discontinued because treatment retention of oral diacetylmorphine was lower than injectable diacetylmorphine maintenance treatment. Finally, two case studies illustrate the limitations and potential problems of oral diacetylmorphine in the treatment of treatment-refractory heroin dependent patients.
Based on all published data, it is unlikely that oral diacetylmorphine produces a substantial 'rush'. Prescription of oral diacetylmorphine might therefore be effective only for treatment-refractory patients with heroin dependence (i) as maintenance treatment for those who never injected or inhaled opioids; (ii) as maintenance treatment for those who want to switch from injection to oral administration of diacetylmorphine; and/or (iii) to reduce opioid withdrawal symptoms.
综述(监督下)口服二乙酰吗啡治疗重度海洛因依赖患者的药代动力学、药效学和临床疗效及安全性的科学文献。
检索PubMed、Embase、Web of Science 和 PsycINFO 数据库。根据既定的纳入和排除标准,确定并选择了 11 项已发表的研究。
四项药代动力学研究报告二乙酰吗啡及其活性代谢物 6-单乙酰吗啡的血浆浓度可忽略不计。在六项药效学研究中,三项试验表明口服二乙酰吗啡可减轻阿片类戒断症状,一项开放性先导试验报告称两名患者口服二乙酰吗啡后出现适度的“快感”,两项研究发现患者无法区分口服二乙酰吗啡、美沙酮或吗啡。关于临床研究,一项瑞士前瞻性队列研究显示,口服二乙酰吗啡治疗的保留率较高,严重不良事件较少,而在加拿大 SALOME 试验中,由于口服二乙酰吗啡治疗的保留率低于注射二乙酰吗啡维持治疗,因此提前停止了口服二乙酰吗啡治疗。最后,两项病例研究说明了口服二乙酰吗啡在治疗治疗抵抗性海洛因依赖患者方面的局限性和潜在问题。
基于所有已发表的数据,口服二乙酰吗啡不太可能产生实质性的“快感”。因此,对于治疗抵抗性海洛因依赖患者(i)从未注射或吸入过阿片类药物的患者作为维持治疗;(ii)希望从注射转为口服二乙酰吗啡维持治疗的患者;和/或(iii)减轻阿片类戒断症状,处方口服二乙酰吗啡可能是有效的。